Results 171 to 180 of about 50,237 (216)

A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer. [PDF]

Oncol Res
Wang C, Huang M, Li W, Sheng X, Zhao X, Zhu X, Chen Z, Zhang Z, Li H, Guo W.   +9 more
europepmc   +1 more source

Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. [PDF]

J Clin Invest
Cho H, Seo Y, Sohn H, Choudhary SK, Skinner J, Zhao M, Krymskaya L, Zhong W, Lack J, Li S, Traore B, Tan J, Commins SP, Crompton PD.   +13 more
europepmc   +1 more source

Overcoming cetuximab resistance in HNSCC by Hsp90 inhibition to enhance EGFR degradation. [PDF]

J Biol Chem
Mehta RK, Tan M, Suresh K, Lawrence TS, Nyati MK.   +4 more
europepmc   +1 more source

Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers. [PDF]

J Exp Clin Cancer Res
Vigneron E, Vignau J, Lowyck O, Van den Bossche V, Ambroise J, Kieffer Y, Mechta-Grigoriou F, Rizzi I, Giolito MV, Desgres M, Zaryouh H, Wouters A, Mendola A, Dahou H, Leclerc M, Boidot R, Warnant A, Larondelle Y, Feron O, Machiels JP, Schmitz S, Corbet C.   +21 more
europepmc   +1 more source

α-ketoglutarate accumulation orchestrates immunosuppressive metabolic remodeling to drive cetuximab resistance in metastatic colorectal cancer. [PDF]

Cell Death Dis
Zhu Y, Liu K, Chang L, Lu J, Tang H, Zhu Z, Chen Z, Wang X, Xiao J.   +8 more
europepmc   +1 more source

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking. [PDF]

J Biol Eng
Mestre Borras A, Mehari H, Bitzios A, Zelepukin I, Ud-Din M, Xu T, Li S, Orlova A, Tolmachev V, Ståhl S, Vorobyeva A, Löfblom J.   +11 more
europepmc   +1 more source

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source

Therapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies. [PDF]

Front Genet
Meng Y, Sun J, Ma Y, Kong C.
europepmc   +1 more source

Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial. [PDF]

J Gastrointest Oncol
Kou F, Wang X, Li J, Wang Z, Xu T.
europepmc   +1 more source